HEALTH: Could the Common dandelion help with the WuFlu?

“Well, I’m not a doctor, I have never played one on TV, and I didn’t stay at a Holiday Inn Express last night, but here are some simple thoughts.”

https://www.biorxiv.org/content/10.1101/2021.03.19.435959v1.full

Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro

Posted March 19, 2021.

This article is a preprint and has not been certified by peer review

*** begin quote ***

On 11th March 2020, coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, was declared as a global pandemic by the World Health Organization (WHO). To date, there are rapidly spreading new “variants of concern” of SARS-CoV-2, the United Kingdom (B.1.1.7), the South African (B.1.351) or Brasilian (P.1) variant. All of them contain multiple mutations in the ACE2 receptor recognition site of the spike protein, compared to the original Wuhan sequence, which is of great concern, because of their potential for immune escape. Here we report on the efficacy of common dandelion (Taraxacum officinale) to block protein-protein interaction of spike S1 to the human ACE2 cell surface receptor. This could be shown for the original spike D614, but also for its mutant forms (D614G, N501Y, and mix of K417N, E484K, N501Y) in human HEK293-hACE2 kidney and A549-hACE2-TMPRSS2 lung cells. High molecular weight compounds in the water-based extract account for this effect. Infection of the lung cells using SARS-CoV-2 spike pseudotyped lentivirus particles was efficiently prevented by the extract and so was virus-triggered pro-inflammatory interleukin 6 secretion. Modern herbal monographs consider the usage of this medicinal plant as safe. Thus, the in vitro results reported here should encourage further research on the clinical relevance and applicability of the extract as prevention strategy for SARS-CoV-2 infection.

*** end quote ***

Common dandelion (Taraxacum officinale) efficiently blocks the interaction between ACE2 cell surface receptor and SARS-CoV-2 spike protein D614, mutants D614G, N501Y, K417N and E484K in vitro
Hoai Thi Thu Tran, Nguyen Phan Khoi Le, Michael Gigl, CorinnaDawid, Evelyn Lamy
bioRxiv 2021.03.19.435959; doi:https://doi.org/10.1101/2021.03.19.435959

# – # – # – # – #

Where’s the coverage?

Like that lady doctor in Peru with peroxide, ivermectin, and vitamins, why haven’t we heard about this?  Either positive or negative.

I know Big Pharma ain’t going to make a lot of money off of dandelions either but where are the Gooferment “scientists” studying this — quickly.

I found it via survival blog can’t they.

—30—

INTERESTING: Merck, the company that invented ivermectin, doesn’t want an off-patent drug

https://anti-empire.com/indication-ivermectin-drastically-reduces-deaths-keeps-trickling-in-from-the-third-world-too-bad-its-a-cheap-generic/

Indication Ivermectin Drastically Reduces Deaths Keeps Trickling in From the Third World. Too Bad It’s a Cheap Generic
Would rain on the virus cult parade
Dr. Sebastian Rushworth

*** begin quote ***

Back in January I wrote an article about four randomized controlled trials of ivermectin as a treatment for covid-19 that had at that time released their results to the public. Each of those four trials had promising results, but each was also too small individually to show any meaningful impact on the hard outcomes we really care about, like death. When I meta-analyzed them together however, the results suddenly appeared very impressive. Here’s what that meta-analysis looked like:

It showed a massive 78% reduction in mortality in patients treated with covid-19. Mortality is the hardest of hard end points, which means it’s the hardest for researchers to manipulate and therefore the least open to bias. Either someone’s dead, or they’re alive. End of story.

You would have thought that this strong overall signal of benefit in the midst of a pandemic would have mobilized the powers that be to arrange multiple large randomized trials to confirm these results as quickly as possible, and that the major medical journals would be falling over each other to be the first to publish these studies.

That hasn’t happened.

*** and ***

I understand why pharmaceutical companies don’t like ivermectin. It’s a cheap generic drug.

Even Merck, the company that invented ivermectin, is doing it’s best to destroy the drug’s reputation at the moment. This can only be explained by the fact that Merck is currently developing two expensive new covid drugs, and doesn’t want an off-patent drug, which it can no longer make any profit from, competing with them.

The only reason I can think to understand why the broader medical establishment, however, is still so anti-ivermectin is that these studies have all been done outside the rich west. Apparently doctors and scientists outside North America and Western Europe can’t be trusted, unless they’re saying things that are in line with our pre-conceived notions.

*** end quote ***

Follow the money!

Just like DJT45 said!

—30—